Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals, Inc. reported third-quarter 2026 total revenue of $1,458.1 million, compared with $1,249.0 million in 2025. Net product revenue was $1,291.9 million versus $851.1 million, including AMVUTTRA revenue of $1,130.4 million versus $685.3 million. Collaboration revenue was $71.5 million versus $351.7 million, while royalty revenue was $94.7 million versus $46.2 million.
Net income was $2,167.3 million, compared with $292.7 million, and included an income tax benefit of $1,871.5 million. For the nine months ended September 30, 2026, total revenue was $3,916.2 million and operating cash flow was $738.2 million, compared with $2,616.9 million and $306.4 million, respectively, in 2025. At September 30, 2026, cash and cash equivalents were $1,754.3 million and marketable debt securities were $1,832.9 million. Alnylam believes its cash, marketable securities, expected product and collaboration revenue, and available borrowing capacity would be sufficient for near-term capital and operating needs for at least the next 12 months.
Alnylam Pharmaceuticals, Inc. reported third-quarter 2026 revenue of $1,458.1 million, up 17%; net product revenue was $1,291.9 million, up 52%, including TTR revenue of $1,150.0 million, up 59%. GAAP operating income was $345.8 million, down 6%, and non-GAAP operating income was $424.9 million, down 11%. GAAP net income was $2,167.3 million, including a $1,871.5 million tax benefit, primarily from releasing valuation allowances on certain U.S. federal and state deferred tax assets.
Cash, cash equivalents and marketable securities were $3.6 billion as of September 30, 2026. Alnylam reiterated 2026 guidance: total net product revenue of $4,700 million to $5,100 million and collaboration and royalty revenue of $575 million to $625 million.
TRITON-CM's target enrollment rose from 1,750 to approximately 2,250 patients; nucresiran launch in ATTR-CM remains expected by 2030, assuming positive data and regulatory approval. In the highest brezosiran dose group evaluated, mean CSF mHTT fell 60%-64% from baseline at month 3, with a maximum individual reduction of 83%. A placebo-controlled pivotal study is planned for 2027, pending regulatory alignment.
Alnylam Pharmaceuticals, Inc. (ALNY) EVP, CLO and Secretary Bryan Supran reported 1,758 shares of common stock automatically sold by the company on his behalf at $226.88 per share on October 2, 2026. The mandatory sell-to-cover provision covered minimum statutory tax withholding due upon vesting and settlement of restricted stock units. Supran held 12,807 shares after the transaction. No Rule 10b5-1 plan is reported.
Alnylam Pharmaceuticals, Inc. (ALNY) reported a proposed sale by officer Bryan A. Supran of 1,758 common shares, with an aggregate market value of $398,862.25, for approximately October 2, 2026. Fidelity Brokerage Services LLC is listed as broker, and Nasdaq as the exchange.
The shares are identified as acquired through restricted-stock vesting on October 1, 2026. The remarks state the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
ALNYLAM PHARMACEUTICALS, INC. (symbol: ALNY) is the issuer of record for a Form 4 filing submitted to the SEC. Greenstreet Yvonne reported acquisition or exercise transactions in this Form 4 filing.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported that Chief Executive Officer and director Yvonne Greenstreet received a grant of 107 shares of common stock on September 19, 2026 as a non-cash award recognizing 10 years of continuous employment, issued net of the minimum statutory tax liability. Following this award, she holds 95,802 shares directly and 407 shares indirectly through a managed account reflecting ALNY 401(k) matching contributions. No Rule 10b5-1 trading plan is reported.
Alnylam Pharmaceuticals reported higher revenue for the quarter ended June 30, 2026, with total revenues of 1,290,948, up from 773,689 a year earlier. Net product revenues rose to 1,172,109, led by AMVUTTRA at 1,011,762, while Rare disease products contributed 141,886. The company generated net income of 164,494 for the quarter and 370,485 for the first half, reversing prior-year losses.
Liquidity remains robust, with cash and cash equivalents of 1,708,318 and marketable debt securities of 1,599,829 as of June 30, 2026. Operating cash flow for the first half improved to 397,228. Stockholders’ equity increased to 1,354,118, while convertible debt totaled 1,010,981.
Alnylam continues to advance its RNAi-based pipeline and collaborations. The Roche zilebesiran agreement carried a total transaction price of 1,738,167, with 77,529 in related collaboration revenue recognized year‑to‑date. The company also recorded 51,356 in collaboration revenue from Regeneron and entered an AI‑driven discovery collaboration with Inceptive Nucleics, including a 15,000 preferred equity investment.
Alnylam Pharmaceuticals reported strong second-quarter 2026 results, with total revenues of $1,290,948 thousand, up 67% from Q2 2025. Net product revenues were $1,172,109 thousand, a 74% increase, led by AMVUTTRA and ONPATTRO TTR therapies generating $1,030,223 thousand, an 89% rise.
GAAP income from operations was $231,441 thousand versus a prior-year loss, and GAAP net income reached $164,494 thousand, while non-GAAP net income was $251,801 thousand and diluted non-GAAP EPS was $1.84. Cash, cash equivalents and marketable securities totaled $3.3 billion as of June 30, 2026, supported by net cash inflows from operating activities.
The company updated 2026 guidance to $4,200–$4,500 million in TTR net product revenues and $4,700–$5,100 million in total net product revenues. Expected 2026 net revenues from collaborations and royalties were raised to $575–$625 million, and non-GAAP R&D and SG&A expense guidance of $2,700–$2,800 million was reiterated.
ALNYLAM PHARMACEUTICALS, INC. director David E I Pyott exercised a stock option for 3,830 shares of common stock at a conversion price of $70.20 per share and sold the same 3,830 shares in open-market transactions on June 1, 2026. The reported sales occurred at weighted average prices around $297.71–$302.65 per share under a pre-arranged Rule 10b5-1(c) trading plan, and the options were due to expire on June 3, 2026. Following these transactions, he holds 1,582 shares of common stock directly and 27,900 shares indirectly through the David E I Pyott Trust, of which he is trustee.
ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt reported a compensation-related stock option grant. He received options to buy 4,393 shares of common stock at an exercise price of $295.63 per share. The options vest in three equal annual installments starting on the first anniversary of the grant date and expire in 2036. Following this grant, he holds 4,393 derivative securities directly.
ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing lists him as a director of the company but does not report any stock transactions or specific holdings in this excerpt.